Abdalla MMI. Serum resistin and the risk for hepatocellular carcinoma in diabetic patients. World J Gastroenterol 2023; 29(27): 4271-4288 [PMID: 37545641 DOI: 10.3748/wjg.v29.i27.4271]
Corresponding Author of This Article
Mona Mohamed Ibrahim Abdalla, MSc, PhD, Senior Lecturer, Department of Human Biology, School of Medicine, International Medical University, No. 126, Jln Jalil Perkasa 19, Bukit Jalil 57000, Kuala Lumpur, Malaysia. monamohamed@imu.edu.my
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jul 21, 2023; 29(27): 4271-4288 Published online Jul 21, 2023. doi: 10.3748/wjg.v29.i27.4271
Serum resistin and the risk for hepatocellular carcinoma in diabetic patients
Mona Mohamed Ibrahim Abdalla
Mona Mohamed Ibrahim Abdalla, Department of Human Biology, School of Medicine, International Medical University, Bukit Jalil 57000, Kuala Lumpur, Malaysia
Author contributions: Abdalla MMI collected the data and wrote the paper.
Conflict-of-interest statement: The author declares no conflict of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mona Mohamed Ibrahim Abdalla, MSc, PhD, Senior Lecturer, Department of Human Biology, School of Medicine, International Medical University, No. 126, Jln Jalil Perkasa 19, Bukit Jalil 57000, Kuala Lumpur, Malaysia. monamohamed@imu.edu.my
Received: April 26, 2023 Peer-review started: April 26, 2023 First decision: May 27, 2023 Revised: June 11, 2023 Accepted: June 27, 2023 Article in press: June 27, 2023 Published online: July 21, 2023
Core Tip
Core Tip: Resistin, a hormone linked to the onset of insulin resistance and diabetes, could be involved in the development and advancement of hepatocellular carcinoma (HCC) in individuals with diabetes. Increased resistin levels have been observed in HCC patients and might be connected to a more severe disease stage and unfavourable prognosis. This review aims to assess the existing literature concerning the possible application of resistin as a biomarker for HCC development and monitoring while investigating the potential processes through which resistin influences HCC’s development and progression in diabetic patients. Gaining a better understanding of these processes may offer valuable insights for the prevention and therapy of this condition.
